After Hours Gainer
AKTX Akari Therapeutics PLC - American Depositary Shares5.14+1.71+49.9%
After Hours:11.50+6.36 (+123.7%)
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
Globe NewswireThu, 21-May 5:01 PM
After Hours:7.85+2.71 (+52.7%)
Premarket Decliner
AKTX Akari Therapeutics PLC - American Depositary Shares5.80+0.68+13.3%
Premarket:4.90-0.90 (-15.5%)
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Globe NewswireMon, 20-Apr 8:35 AM
Premarket Gainer
AKTX Akari Therapeutics PLC Ads2.06+0.03+1.5%
Premarket:2.80+0.74 (+35.9%)
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
Globe NewswireMon, 2-Dec 8:30 AM
AKTX Akari Therapeutics PLC Ads1.80+0.03+1.9%
Premarket:2.63+0.83 (+46.1%)
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
Globe NewswireWed, 14-Aug 8:00 AM
AKTX Akari Therapeutics PLC ADR3.35+0.23+7.4%
Premarket:4.08+0.73 (+21.8%)
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
Globe NewswireTue, 23-Apr 8:31 AM
